Zobrazeno 1 - 10
of 1 418
pro vyhledávání: ''
Autor:
Kazuki Furuhashi, Katsuhiro Yoshimura, Masato Karayama, Noriyuki Enomoto, Naoki Inui, Hironao Hozumi, Takafumi Suda, Yutaro Nakamura, Yuzo Suzuki, Yusuke Inoue, Tomoyuki Fujisawa
Publikováno v:
Journal of Immunotherapy. 45:125-131
The nutritional status has the potential to affect cancer immunity. We evaluated the relationship between the nutritional status and the efficacy of nivolumab in patients with non-small cell lung cancer (NSCLC). This study was a post hoc analysis of
Autor:
Jennifer Y Ju, Paul R. Kunk, Kevin T. Lynch, Kevin Winters, Max O. Meneveau, Osama E. Rahma, Joseph M. Obeid, Sean C. Dougherty, Todd W. Bauer, Edward B. Stelow, Craig L. Slingluff, Rachel Whitehair
Publikováno v:
J Immunother
Cholangiocarcinoma (CC) is an uncommon malignancy with increasing incidence and dismal prognosis. We conducted a comprehensive analysis of the CC tumor immune microenvironment (TIME) based on tumor location to identify therapeutic targets. We hypothe
Publikováno v:
Journal of Immunotherapy. 44:234-238
Immunotherapy has revolutionized the treatment of advanced cutaneous squamous cell carcinoma. However, the role of immune checkpoint inhibitors for the treatment of Marjolin ulcer (MU), a rare cutaneous malignancy that arises from previously traumati
Autor:
Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, Samuel Funt, Chung-Han Lee, Han A Li, Gopa Iyer, Jonathan E. Rosenberg, Ashely M Regazzi, Dean F. Bajorin, Irina Ostrovnaya
Publikováno v:
J Immunother
Eosinophils influence antitumor immunity and may predict response to treatment with immune checkpoint inhibitors (ICIs). To examine the association between blood eosinophil counts and outcomes in patients with advanced or metastatic urothelial carcin
Publikováno v:
Journal for immunotherapy of cancer. 10(8)
BackgroundTo evaluate factors affecting the utilization of immunotherapy and to stratify results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in 2014, an analysis of available data from the National Cancer Database (N
Autor:
Shailender Bhatia, Paul Nghiem, S Phani Veeranki, Alejandro Vanegas, Kristina Lachance, Lisa Tachiki, Kevin Chiu, Emily Boller, Murtuza Bharmal
Publikováno v:
Journal for immunotherapy of cancer. 10(8)
BackgroundMerkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine neoplasm with annual incidence rates of 0.13–1.6 cases/100,000/year worldwide as of 2018. Chemotherapy for metastatic MCC (mMCC) has high objective response rates
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Michael B. Atkins, Dongyu Zhang, Tomi Akinyemiju, Tina D. Tailor, Chul Kim, Dejana Braithwaite
Publikováno v:
J Immunother
In patients with metastatic non-small cell lung cancer (mNSCLC), the extent to which immunotherapy utilization rate varies by comorbidities is unclear. Using the National Cancer Database (NCDB) from 2015 to 2016, we assessed the association between l
Publikováno v:
Journal of Immunotherapy. 44:243-247
The immune checkpoint inhibitors have improved the standards of care in cancer treatment and have dramatically improved patient prognoses. These new antibodies turned to be an integral part of the standard of care for metastatic small-cell lung cance
Autor:
Sakti Chakrabarti, Leslie Bucheit, Jason Scott Starr, Racquel Innis-Shelton, Ardaman Shergill, Hiba Dada, Regina Resta, Stephanie Wagner, Naomi Fei, Pashtoon Murtaza Kasi
Publikováno v:
Journal for immunotherapy of cancer. 10(6)
Clinical trials reporting the robust antitumor activity of immune checkpoint inhibitors (ICIs) in microsatellite instability-high (MSI-H) solid tumors have used tissue-based testing to determine the MSI-H status. This study assessed if MSI-H detected